TY - JOUR T1 - Histopathologist Features Predictive of Diagnostic Concordance at Expert Level Amongst a Large International Sample of Pathologists Diagnosing Barrett’s Dysplasia Using Digital Pathology JF - medRxiv DO - 10.1101/19000174 SP - 19000174 AU - Myrtle J. van der Wel AU - Helen G. Coleman AU - Jacques JGHM Bergman AU - Marnix Jansen AU - Sybren L. Meijer AU - on behalf of the BOLERO working group Y1 - 2019/01/01 UR - http://medrxiv.org/content/early/2019/06/25/19000174.abstract N2 - Objective Guidelines recommend expert pathology review of Barrett’s oesophagus (BO) biopsies that reveal dysplasia, but there are no evidence-based standards to corroborate expert reviewer status. We investigated BO concordance rates and pathologist features predictive of diagnostic discordance amongst a large international cohort of gastrointestinal pathologists to develop a quantitative model of BO expert review.Design Pathologists (n=55) from over 20 countries assessed 55 digitised BO biopsies from across the diagnostic spectrum, before and after viewing matched p53 immunohistochemistry. Extensive demographic and clinical experience data were obtained via online questionnaire. We calculated discordance rates and applied multivariate regression analyses to identify predictors of concordance.Results We recorded over 6,000 individual case diagnoses. Of 2,805 H&E diagnoses, we found excellent concordance (>70%) for non-dysplastic Barrett’s oesophagus (NDBO) and high-grade dysplasia (HGD), and intermediate concordance for low-grade dysplasia (LGD, 42%) and indefinite for dysplasia (IND, 23%). Major diagnostic errors (i.e. NDBO overinterpreted as LGD/HGD or vice versa) were found in 248 diagnoses (8.8%), which reduced to 8.3% after viewing p53 labelled slides. At least 5 years of professional experience was protective against major diagnostic error for H&E slide review (OR 0.48, 95%CI 0.31-0.74). Working in a district general hospital was associated with increased odds of major diagnostic error (OR 1.76, 95%CI 1.15-2.69), however this was neutralised when pathologists viewed p53 labelled slides, suggesting a beneficial impact of p53 immunohistochemistry for this group.Conclusion We have developed an evidence-based quantitative model of BO histopathology diagnosis at expert consensus level that will inform guideline development.Competing Interest StatementThe authors have declared no competing interest.Funding StatementHJC and MJ are funded by Cancer Research UKAuthor DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.NAAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.NAI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesAll primary data will be made available upon requestBOBarrett’s oesophagusBMIbody mass indexCIconfidence intervalCRFcase record formOACoesophageal adenocarcinomaHGDhigh-grade dysplasiaIHCimmunohistochemistryIMCintramucosal carcinomaINDindefinite for dysplasiaIQRinterquartile rangeKkappa valueLGDlow-grade dysplasiaNDBOnon-dysplastic Barrett’s oesophagusORodd’s ratioWSIwhole slide imaging ER -